Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Ovarian Cancer treatment details. Chemotherapy. Hôpital Hôtel-Dieu, Paris, France

Survival: 32.0 months
Toxicity Grade: 3
Treatments: Chemotherapy
Drugs: Doxil
Country: France
City/State/Province: Paris
Hospital: Hôpital Hôtel-Dieu
Journal: Link
Date: 11/2006

Patients: This phase II trial involved 104 women with advanced ovarian cancer that had relapsed. All patients had been pretreated with platinum and taxane. The median age was 61, ranging from 23-79.

Treatment: Treatment consisted of two chemotherapeutic agents: pegylated liposomal doxorubicin (Doxil®, CAELYX®) and carboplatin.

Toxicity: Grade 3 toxicities included nausea/vomiting, mucositis, infection, neuropathy, asthenia, and hypersensitivity. Grade 3 toxicities were observed in 1-7% of the patients. More common were grade I and II toxicities, including alopecia, nausea/vomiting, mucositis, neuropathy, and asthenia.

Results: The median overall survival time was 32 months. The median progression-free survival was 9.4 months.

Support: This study was supported by a grant from Schering-Plough, France. Schering-Plough markets pegylated liposomal doxorubicin under the trade name CAELYX®.

Correspondence: Dr. E Pujade-Lauraine

E-mail to a Friend Email Physician More Information